Heather Woolery-Lloyd, MD, FAAD reviews the case of a 12-year-old patient with moderate-to-severe acne, focusing on how to navigate appropriate treatment decisions and patient factors that indicate when a patient is an ideal candidate for isotretinoin.
Rocco Serrao, MD, FAAD, addresses potential barriers to access and affordability of narrowband UVB phototherapy and topical medications for vitiligo treatment, while highlighting available resources to assist patients in overcoming these obstacles.
Rocco Serrao, MD, FAAD, discusses a case of a 38-year-old male with progressive vitiligo, exploring potential triggers and exacerbating factors, as well as lifestyle changes and treatment options to manage symptoms and improve quality of life.
Dr Serrano, shares insights on the panel’s advice given to their patients with vitiligo who have achieved remission through treatment with ruxolitinib, while also addressing the challenges of navigating payer coverage for vitiligo treatments and strategies for dealing with coverage denials.
Rocco Serrao, MD, FAAD, a board-certified dermatologist, discusses a case of vitiligo involving a 20-year-old male patient who presents with white patches on his face that have persisted for 6 weeks without any relevant chemical exposures, and emphasizes the importance of providing counseling and support to address the potential impact on the patient's self-esteem and confidence.
In this recently presented poster, a dermatology expert draws on clinical experience to reveal why healthcare providers switch treatments for atopic dermatitis (AD). The expert also examines how these reasons vary with disease stage and patient demographics, offering nuanced insights into AD management.
Kristine Kucera, PA-C, MPAS, DHS, and Mickey Bryson discuss Mickey's atopic dermatitis diagnostic process and the ineffective initial treatments, which included topical therapies, homeopathic remedies, and prednisone steroids.
Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative.
Dr. Matthew J. Zirwas, evaluates a 45-year-old woman with worsening, highly itchy dermatitis on her hands and arms, notably her fingertips. He addresses management strategies for her condition, which has deteriorated over four months, leading to painful fissures
Matthew J. Zirwas, MD, , presents a complex case study of a 63-year-old male patient with atopic dermatitis presenting as a chronic, severe pruritic rash on his back, upper arms, and upper thighs. His condition has persisted consistently for the past three months despite a history of intermittent occurrences over several years.
Mona Shahriari, MD, explores potential areas of research that can contribute to continuous improvement in pediatric atopic dermatitis management.
Mona Shahriari, MD, expands on benefits of ruxolitinib in managing itch and inflammation in pediatric atopic dermatitis.
Michael Cameron, MD, identifies comorbidities, lifestyle factors, and educational opportunities AAD guidelines provide insight on for patients with atopic dermatitis.
Michael Cameron, MD, identifies the most important pearls from the latest atopic dermatitis treatment guidelines set forth by the American Academy of Dermatology.
Sonya Kenkare, MD, explains her approach to itch and the support system of multiple specialties to help a pediatric patient with atopic dermatitis.
Sonya Kenkare, MD, details where ruxolitinib fits within the current landscape of pediatric atopic dermatitis treatments.
Lisa Swanson, MD, FAAD, sheds light on the enhanced accessibility of ruxolitinib cream, highlighting its improved availability for patients in need.
Brad Glick, DO, MPH, FAAD, notes the absence of location restrictions with topical ruxolitinib cream, distinguishing it from topical corticosteroids. The panel discusses the cyclic pattern of steroid use and the potential of ruxolitinib cream as a continuous treatment option.
Dermatology experts evaluate topical ruxolitinib cream's effectiveness in rapidly relieving itch and offer guidance on its black box warning. They also discuss its efficacy in children under 2, highlighting its suitability for those with tactile sensitivity.
Dr James Del Rosso underscores the importance of phase 2 and dose-ranging studies to uncover efficacy differences between therapies, while the panel explores how clinical data from ruxolitinib trials mirrors real-world outcomes.
James Del Rosso, DO, Brad Glick, DO, MPH, FAAD, and Lisa Swanson, MD, FAAD, address the demand for non-steroidal treatment alternatives while navigating the individualization of data interpretation regarding these treatments.
Dr. Alexandra Golant shares invaluable practice pearls for optimizing the management of hand and foot atopic dermatitis with the use of systemic treatments.
Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives. She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment.
Dr Golant continues with the case of the 38-year old patient with atopic dermatitis and explore effective strategies for navigating treatment selection and planning in this condition, focusing on discussing options with patients and instilling confidence in the chosen approach.
Alan Irvine, MD, DSc, shares insights on the impact of ruxolitinib on quality of life in pediatric patients and 2024 AAD research presentations to take into consideration.
Dr Linda Stein Gold and Dr Michael Cameron assess the safety and tolerability of topical ruxolitinib cream, offering guidance on counseling patients about the black box warning. They also address the perception of limited treatment access and strategies for overcoming this barrier.
Alan Irvine, MD, DSc, offers an understanding of BSA changes and anti-inflammatory effects of ruxolitinib in the latest research presented.
Ruth Ann Vleugels, MD, MPH, MBA, delves into patient-specific considerations and action plans when on a JAK inhibitor, including shingles prevention and management.
Experts in dermatology review the rapid itch relief provided by topical ruxolitinib cream and attribute its fast-acting efficacy to its mechanism of action targeting a variety of interleukins.
Linda Stein Gold, MD, and Michael Cameron, MD, FAAD, discuss the need for non-steroidal treatment options in atopic dermatitis management, driven by patient preferences. They highlight the challenges with previous oily options, which often caused tolerability and irritation issues, and how the approval of ruxolitinib cream addresses these concerns.
